Introduction

S
arcomatoid carcinoma of the kidney is a rare histology that is encountered after radical nephrectomies. As of today, the prognosis has been poor with standard therapeutic principles that are being extrapolated from the management of clear cell renal cancer. Due to the rarity, the prognostication, need for adjuvant therapies, need for adding systemic chemotherapy for metastatic disease, contribution of cytoreductive nephrectomy and various other aspects have not been addressed properly. We only have data from a few case reports on how to manage this patient subset. Here, we present a similar case and review the data till now on management.
Case Report
A 58-year-old male, who was hypertensive, on medications and well controlled, presented to us with the complaints of low-grade fever and weakness for 2 months. There was no history of any weight loss or any other localizing symptoms. On routine investigation at local place, a complete blood count suggested leucocytosis. Suspected of a haematological malignancy, he was referred to our hospital for further management.
At presentation, he was alert and conscious. His vitals were pulse: 82/min regular, blood pressure: 150/90, respiratory rate: 22/min and temperature: 98 degrees F. He had pallor, with no evidence of jaundice or oedema. No nodes were palpable in the neck or other sites. Chest examination was normal. Abdomen examination did not reveal any organomegaly. Rest of the systemic examination was within normal limits.
On investigation, haemoglobin was 5.4 gm/dl, red blood cell indices normocytic, normochromic with a total leucocyte count of 66,000/cu mm. Differential count was N65 L25 E3 B3 M4. Creatinine was 1.5 mg/dl, urea 40 mg/dl and liver functions were within normal limits. Chest X-ray was done to rule out any infective foci, and it was normal. All his laboratory parameters are summarised in Table 1. In view of raised counts and low-grade fever, he was started on oral antibiotics with a presumption of an infective cause. However, after 5 days of oral antibiotics, repeat complete blood count (CBC) was done, which showed no change in the total leukocyte count. CRP was done this time, which was normal. To differentiate it from myeloproliferative disorder, we sent the LAP score, which was 1.5× times the upper limit of normal for the reference range of the lab. So, we started investigating for any underlying cause for leucocytosis. A CECT of abdomen/pelvis was done, which revealed a renal mass in the He was planned for systemic therapy with sunitinib. However, the patient as well as the relatives did not want any further treatment and wanted to go for alternative therapy. So, he was discharged from the hospital with proper counselling about the prognosis. Unfortunately, the patient came back to us after 15 days with acute respiratory failure. He was taken to ICU and started on mechanical ventilation with vasopressor support. But he could not be salvaged and died of severe metabolic acidosis.
Review of Literature
Renal cell carcinoma, based on the data from developed countries, is considered to be the malignancy of the sixth and seventh decade of life. As per the Globocan data, it is the ninth most common cancer in the world. In India, many patients present at a younger age and in advanced stage of the disease. Incidence globally is around 2.1 lakhs, out of which, mortality is around 90,000.
[1]
It is estimated that 10-40% of patients develop paraneoplastic syndromes. [2] The most common syndromes are hypocalcaemia, hypertension, polycythaemia, hepatic dysfunction and constitutional symptoms. [3] In some series, the presence of paraneoplastic syndromes has conferred poor prognosis. [4] The presence of leucocytosis at presentation is very rare. Some of them have been described in animals. Data in human beings are still a few. One case report has shown increased levels of G-CSF as a cause of leukocytosis. [5] In another case report from the Netherlands, a 79-year-old female with RCC presented with low-grade fever, weight loss and overt granulocytosis and thrombocytosis. They demonstrated increased levels of IL-1alpha, IL-1beta, IL-8 and ICAM-1 in the tumour with systemic elevated levels of IL-6 and IL-8 with secondary increased serum G-CSF and TPO levels. [6] Another pair case report from Huang et al. showed the presence of leukemoid reaction after nephrectomy was done. [7] One case of papillary carcinoma of kidney also presented with baseline leukocytosis. [8] upper pole of the right kidney, 7 cm in largest diameter with heterogeneous enhancement. The radiological picture was suggestive of renal cell carcinoma. Metastatic workup with the CECT of thorax revealed multiple lung metastases. He did not have any bone pain and serum ALP was normal, so bone scan was not done. Heng's score was calculated, which came out to be intermediate risk. With proper explanation of the disease prognosis and outcomes, we did right radical nephrectomy after proper optimisation of haemoglobin, which is the standard procedure for metastatic renal cell carcinoma. Our case is unique about the fact that a rare variant of renal cell carcinoma has presented with a rare paraneoplastic feature. This case underlines the importance of searching for an underlying malignancy, when we diagnose a case of leucocytosis, without any evidence of hematologic malignancy. The outcome of sarcomatoid carcinoma of kidney is very poor. The incidence of metastatic disease is extremely high at presentation, with 45-84% having evidence of systemic disease. [9] [10] [11] One-and two-year overall survival rates were 48 and 37%, respectively, in one study, in the interleukin era. [11] In one study by Kwak et al., the survival of sarcomatoid variant was found to be 3.2 months compared to nonsarcomatoid variant. [12] In conclusion, renal cell carcinoma can rarely present with nonspecific weakness and leucocytosis resembling myeloproliferative disorder. The recognition of the underlying cause of leucocytosis should be of utmost importance, because of the need of early institution of best possible therapy in this poor prognostic subset of patients.
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